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Topical Steroids to Treat Granulomatous Mastitis: A Case 
Report 
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Department of General Surgery, Sakarya University Faculty of Medicine, Sakarya, Turkey
Idiopathic granulomatous mastitis (IGM) is a rare and chronic benign disease of the breast. Histologically, the disease 
presents as an intense inflammatory reaction with non-caseated granulomas that are the characteristic symptom of the 
disease. No consensus exists on the best treatment modality for this disease. In this report, we present a patient with 
granulomatous mastitis who was treated successfully with low-dose oral and topical steroids. Our aim here is to discuss 
various approaches for IGM in view of the literature and present treatment with topical steroids, which has not been 
reported.
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INTRODUCTION
Idiopathic granulomatous mastitis (IGM), which 
was first described as a clinical entity by Kessler and 
Wolloch [1] in 1972, is a benign, chronic, and rare breast 
disease that histologically presents with non-caseated 
granulomas. It may be confused with breast cancer both 
clinically and radiologically. Although its etiology has 
not been explained definitively, various factors including 
autoimmunity are probably involved [2]. No consensus 
exists on the best treatment modality for the disease [2-5]. 
We present an IGM case that was successfully treated with 
low dose oral and topical steroids and provide information 
on the use of topical steroids, which has not been reported 
yet.
CASE REPORT
A 32-year-old, married, female patient (para 1) 
presented with pain, redness, enlargement, and hardening 
of the right breast (Fig. 1). A physical examination 
revealed a hyperemic right breast that was larger than 
the contralateral one. The entire breast was edematous, 
firm, and painful on palpation. An axillary examination 
showed no lymphadenopathy. Mammography revealed 
an asymmetric density increase with indistinct margins 
in the retroareolar region and upper outer quadrant 
of the right breast. No microcalcification was evident. 
Breast ultrasonography showed no distinct loculated 
fluid; however, all of the mammary tissue was edematous. 
A breast magnetic resonance image (MRI) revealed 
thickening of the mammary skin of the right breast 
alongside nodular lesions in different locations and of 
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various sizes, which exhibited low signal intensity on 
T1-T2A sequences but displayed no distinct contrast 
enhancement (Fig. 2). A Tru-cut biopsy was performed, 
and the  histopathological analysis of the material showed 
giant granulomas without necrosis. No caseating necrosis 
or vasculitis signs were present (Fig. 3).   
Because of a history of peptic ulcer disease, the oral 
steroid dose was kept at low levels, and a topical steroid 
was applied additionally due to the presence of serious 
cutaneous symptoms. The patient was administered 30 
mg/day oral prednisolone and bid topical prednacinolone 
four times per week (prednol pomade). At the fifth 
week of treatment, the firmness in the mammary tissue 
disappeared, the fistulas closed, and the size of the breast 
was equal to the contralateral one. During the course of 
the oral and topical steroid therapies, the patient received 
peptic ulcer treatment (lansoprazole and sucralfate) 
and antibiotic therapy (ampicillin-sulbactam) against 
secondary infections that might arise from the skin. Eight 
weeks after the discontinuing treatment, recurrence 
was detected in the form of hyperemic areas localized in 
the mammary skin, and the patient was administered 
additional topical steroid. The clinical symptoms resolved 
Figure 1. Pretreatment clinical findings. Redness, enlargement, 
and hardening of the right breast. 
Figure 2. Pretreatment breast magnetic resonance image. Mass 
lesions non-suggestive of a specific diagnosis, inflammatory 
appearance of the parenchyma, and remarkable thickening in 
the mammary skin of the right breast.
Figure 3. Histopathological view. Histiocytes, plasma cells, 
lymphocytes, and Langerhans giant cells formed granulomas. 
The high number of neutrophils was remarkable (H&E, × 10).
Figure 4. Post-treatment breast magnetic resonance image 
(MRI). Normal breast MRI findings (inflammation of the 
pretreatment mammary parenchyma and skin is not present).358    The Korean Journal of Internal Medicine Vol. 26, No. 3, September 2011
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in 4 weeks after repeated four times per week bid topical 
steroid therapy. Controls performed during the fifth 
follow-up month included a breast examination and MRI, 
both of which showed a normal breast (Fig. 4). The patient 
demonstrated no recurrence at the 14th month of follow-
up.   
DISCUSSION
Since its first description in 1972, IGM had challenged 
clinicians regarding diagnosis, differential diagnosis, 
and treatment options. It is a difficult disease in terms of 
diagnosis because the incidence is rare, and the disease 
may not be recognized by clinicians who have no special 
training or interest in breast diseases. Because the 
presenting clinical and radiological signs and symptoms 
mimic those seen in cancer cases, the disease might be 
evaluated as breast cancer, and treatment may be planned 
based on this conclusion. 
IGM has no specific radiological appearance, and 
symptoms often mimic breast cancer. Lee et al. [6] 
reported a thickening (64%) of mammary skin on 
mammography. In our case, no calcification or thickening 
of the mammary skin was observed, but the edema and 
thickening of the mammary skin were remarkable on 
MRI.  
No consensus exists on the most appropriate treatment 
modality for IGM. Many treatment options have been 
presented in the literature, varying from conservative 
therapy to mastectomy [2-5]. Today, the most commonly 
applied treatment options are surgical excision and steroid 
therapy. Systemic corticosteroid therapy was first proposed 
by DeHertogh et al. [7] who reported successful results. 
Recently, successful results have been reported with 
lower doses of steroids. Su et al. [3] reported successful 
treatment by applying 40 mg/day prednisolone to patients 
with a history of gestational diabetes, whereas Maffini 
et al. [8] reported successful outcomes by administering 
systemic antibiotic therapy and 25 mg/day prednisone. No 
data are available on the sole or combined use of topical 
steroids for treating IGM. Topical corticosteroids are used 
to treat many skin diseases, particularly atopic dermatitis, 
due to their anti-inflammatory, vasoconstrictive, 
antiproliferative, and immunosuppressive effects. While 
steroids can be easily absorbed through normal skin, their 
absorption increases during skin inflammation. Because 
of their local and systemic side effects and the potential 
to develop tolerance, steroid use at a frequency of more 
than twice per day is not recommended [9]. Although the 
duration of topical steroid use should be short, studies 
have reported the absence of side effects such as skin 
thinning, atrophy, or hypothalamic-hypophyseal-adrenal 
axis suppression as a result of 16-24 week long therapies 
[10]. In our case, topical steroid therapy was applied four 
days per week bid along with oral steroid treatment. Eight 
weeks after the end of treatment, only the topical steroid 
was used at the recurrence. No local or systemic side 
effects were observed during the use of oral and topical 
steroids. 
In conclusion, we believe that non-invasive treatments 
should be preferred initially because of the self-limiting 
nature of IGM, and topical steroid therapy may prove 
useful, as it affects mammary parenchyma as well as 
mammary skin. Further studies with a greater number of 
patients are needed to determine the oral steroid therapy 
dose and to better understand the efficacy of topical 
steroids for treating IGM. 
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